MedPath

Clinical Trial of CSMed Wound Dressing for Radiation Dermatitis

Phase 1
Completed
Conditions
Radiation Dermatitis
Interventions
Drug: CSMed Dressing
Registration Number
NCT06001463
Lead Sponsor
Chung Shan Medical University
Brief Summary

Investigate the effects of CSMed® for preventing and managing radiation dermatitis in patients with Breast cancer and Head-Neck cancer receiving radiotherapy (≥50 Gy).

Detailed Description

A prospective study was conducted at the University Hospital Medical Center. The patient received part of the breast/neck skin CSMed® dressing or clinical routine skin care. Record the difference between the part of the skin with dressing and undressed skin for each patient. The severity of acute radiation dermatitis was graded using the RTOG clinical scoring standard. From the beginning of the treatment to 4 weeks after the end of the treatment, skin pain, itching, local fever and tightness, as well as skin healing time were collected every week.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients receiving radiation therapy (including undamaged skin and RTOG grade 1 dermatitis).
  • Patients who voluntarily agree to participate in the trial and sign the subject's consent form.
Exclusion Criteria
  • Patients with dermatitis and burns not caused by radiation therapy.
  • Involuntary patients without signed consent.
  • Those who are allergic to the ingredients in this product.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
reduce the severity, and enhance healing of radiation dermatitisCSMed DressingThe patient received part of the breast/neck skin CSMed® dressing or clinical routine skin care.
Primary Outcome Measures
NameTimeMethod
Severity of acute radiation dermatitis4 weeks

The severity of radiation dermatitis can be assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1 to 5.

NCI CTCAE grade 1 - Faint erythema with dry desquamation. NCI CTCAE grade 2 - Moderate dermatitis is characterized by moderate to brisk erythema and patchy, moist desquamation mostly confined to skin folds and creases.

NCI CTCAE grade 3 - There is confluent, moist desquamation in locations other than skin folds.

NCI CTCAE grade 4 - This is characterized by skin necrosis or ulceration of full-thickness dermis.

NCI CTCAE grade 5 - Death due to dermatitis alone is a very rare event.

Radiologists performed radiation therapy according to the needs of clinical diseases. Evaluate and record the case after radiotherapy at 4 weeks, and end the research record.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chung Shan Medical University

🇨🇳

Taichung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath